Muhammad Usman Rashid

List of Publications by Year
in descending order

45 papers	2,303 citations	331670 21 h-index	276875 41 g-index
47 all docs	47 docs citations	47 times ranked	4666 citing authors

#	Article	IF	Citations
1	Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer. JAMA - Journal of the American Medical Association, 2015, 313, 1347.	7.4	390
2	Commonly Studied Single-Nucleotide Polymorphisms and Breast Cancer: Results From the Breast Cancer Association Consortium. Journal of the National Cancer Institute, 2006, 98, 1382-1396.	6.3	238
3	Mutational spectrum in a worldwide study of 29,700 families withBRCA1orBRCA2mutations. Human Mutation, 2018, 39, 593-620.	2.5	224
4	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
5	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. Nature Genetics, 2016, 48, 374-386.	21.4	125
6	Prevalence ofBRCA1 andBRCA2 mutations in Pakistani breast and ovarian cancer patients. International Journal of Cancer, 2006, 119, 2832-2839.	5.1	98
7	Refined histopathological predictors of BRCA1 and BRCA2mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. Breast Cancer Research, 2014, 16, 3419.	5.0	97
8	Interplay between BRCA1 and RHAMM Regulates Epithelial Apicobasal Polarization and May Influence Risk of Breast Cancer. PLoS Biology, 2011, 9, e1001199.	5.6	91
9	Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants. Journal of Clinical Oncology, 2022, 40, 1529-1541.	1.6	90
10	High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. Breast Cancer Research and Treatment, 2007, 103, 225-232.	2.5	86
11	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	12.8	78
12	BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. Cancer Research, 2017, 77, 2789-2799.	0.9	75
13	Characterization of the Cancer Spectrum in Men With GermlineBRCA1andBRCA2Pathogenic Variants. JAMA Oncology, 2020, 6, 1218.	7.1	48
14	Current Status of the Management of Hereditary Breast and Ovarian Cancer in Asia: First Report by the Asian BRCA Consortium. Public Health Genomics, 2016, 19, 53-60.	1.0	42
15	Association of Genomic Domains in BRCA1 and BRCA2 with Prostate Cancer Risk and Aggressiveness. Cancer Research, 2020, 80, 624-638.	0.9	39
16	Association between the BsmI Polymorphism in the Vitamin D Receptor Gene and Breast Cancer Risk: Results from a Pakistani Case-Control Study. PLoS ONE, 2015, 10, e0141562.	2.5	37
17	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	1.3	32
18	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	5.0	31

#	Article	IF	Citations
19	Deleterious RAD51C germline mutations rarely predispose to breast and ovarian cancer in Pakistan. Breast Cancer Research and Treatment, 2014, 145, 775-784.	2.5	28
20	High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients. BMC Cancer, 2016, 16, 673.	2.6	26
21	Spectrum and prevalence of BRCA1/2 germline mutations in Pakistani breast cancer patients: results from a large comprehensive study. Hereditary Cancer in Clinical Practice, 2019, 17, 27.	1.5	24
22	Indoleamine 2,3-dioxygenase: As a potential prognostic marker and immunotherapeutic target for hepatocellular carcinoma. World Journal of Gastroenterology, 2017, 23, 2286.	3.3	23
23	SARS-COV-2 infection and lung tumor microenvironment. Molecular Biology Reports, 2021, 48, 1925-1934.	2.3	22
24	Absence of the BRCA1 del (exons 9â€“12) mutation in breast/ovarian cancer families outside of Mexican Hispanics. Breast Cancer Research and Treatment, 2009, 117, 679-681.	2.5	19
25	Prevalence of TP53 germ line mutations in young Pakistani breast cancer patients. Familial Cancer, 2012, 11, 307-311.	1.9	19
26	Nanomedicine and cancer immunotherapy: focus on indoleamine 2,3-dioxygenase inhibitors. OncoTargets and Therapy, 2017, Volume 10, 463-476.	2.0	17
27	Contribution of BRCA1 large genomic rearrangements to early-onset and familial breast/ovarian cancer in Pakistan. Breast Cancer Research and Treatment, 2017, 161, 191-201.	2.5	13
28	Prevalence and spectrum of MLH1, MSH2, and MSH6 pathogenic germline variants in Pakistani colorectal cancer patients. Hereditary Cancer in Clinical Practice, 2019, 17, 29.	1.5	9
29	Prevalence of PALB2 Germline Mutations in Early-onset and Familial Breast/Ovarian Cancer Patients from Pakistan. Cancer Research and Treatment, 2019, 51, 992-1000.	3.0	9
30	Identification of the deleterious 2080insA BRCA1 mutation in a male renal cell carcinoma patient from a family with multiple cancer diagnoses from Pakistan. Familial Cancer, 2011, 10, 709-712.	1.9	7
31	Absence of the FANCM c.5101C>T mutation in BRCA1/2-negative triple-negative breast cancer patients from Pakistan. Breast Cancer Research and Treatment, 2015, 152, 229-230.	2.5	7
32	In-Silico Analyses of Nonsynonymous Variants in the BRCA1 Gene. Biochemical Genetics, 2021, 59, 1506-1526.	1.7	7
33	Prevalence of RECQL germline variants in Pakistani early-onset and familial breast cancer patients. Hereditary Cancer in Clinical Practice, 2020, 18, 25.	1.5	6
34	Epidemiological Assessment of Oral Cancer Burden in Pakistan. Cancer Investigation, 2021, 39, 842-853.	1.3	5
35	Clinical Characteristics of COVID-19-Infected Cancer Patients in Pakistan: Differences Between Survivors and Non-Survivors. Frontiers in Oncology, 2021, 11, 655634.	2.8	4
36	Association between Cyclooxygenase-2 and Indoleamine 2,3-Dioxygenase Expression in Breast Cancer Patients from Pakistan. Asian Pacific Journal of Cancer Prevention, 2019, 20, 3521-3525.	1.2	4

#	Article	IF	Citations
37	Chasing the origin of 23 recurrent <scp> BRCA1 </scp> mutations in Pakistani breast and ovarian cancer patients. International Journal of Cancer, 2022, , .	5.1	4
38	No association of miscarriage and BRCA carrier status in Pakistani breast/ovarian cancer patients with a history of parental consanguinity. Breast Cancer Research and Treatment, 2009, 116, 211-213.	2.5	3
39	Forkhead box P3 and indoleamine 2,3-dioxygenase co-expression in Pakistani triple negative breast cancer patients. World Journal of Clinical Oncology, 2020, 11, 1018-1028.	2.3	2
40	No association between BRCA mutations and sex ratio in offspring of Pakistani BRCA mutation carriers. Breast Cancer Research and Treatment, 2007, 107, 155-156.	2.5	1
41	<scp>BRCA1</scp> genetic testing in a Pakistani breastâ€ovarian cancer family with multiple consanguineous marriages. Clinical Genetics, 2015, 88, 198-199.	2.0	1
42	INHERITED GENETIC SUSCEPTIBILITY TO BREAST CANCER IN PAKISTAN. Journal of Cancer & Allied Specialties, 2018, 4, .	0.3	1
43	Absence of the TRIP13 c.1060C>T Mutation in Wilms Tumor Patients From Pakistan. Journal of Pediatric Hematology/Oncology, 2020, 42, e128-e131.	0.6	0
44	HOW TO WRITE A SCIENTIFIC RESEARCH PAPER. Journal of Cancer & Allied Specialties, 2017, 3, .	0.3	0
45	Prevalence of FANCM germline variants in BRCA1/2 negative breast and/or ovarian cancer patients from Pakistan. Familial Cancer, 0, , .	1.9	0